StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

BioNexus Gene Lab's price to book ratio was 0.3× on Nov 11, 2026, against 1.2× a year earlier. Over the last 4 years it ranged from 0.3× to 270.3×, with a median of 7.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.3×−0.8
2025Dec 31, 20251.0×−4.3
2024Dec 31, 20245.4×−4.8
2023Dec 29, 202310.1×−89.3
2020Aug 31, 202099.4×–

More BioNexus Gene Lab figures

See a number that looks wrong?